Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04688775 · ClinicalTrials.gov registry record · Phase 3
Eptinezumab in Participants With Episodic Cluster Headache
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 231
- Enrollment target
NCT04688775 is a Phase 3 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 231 participants.
The verdict
NCT04688775, a Phase 3 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 231 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of eptinezumab in participants with episodic Cluster Headache (eCH)
Interventions
- DRUG Placebo
- DRUG Eptinezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2020-12-23 |
| Est. Completion | 2023-10-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04688775
The ClinicalTrials.gov registry entry for NCT04688775 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04688775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04688775 about?
NCT04688775 is a clinical study titled "Eptinezumab in Participants With Episodic Cluster Headache". The purpose of this study is to evaluate the efficacy of eptinezumab in participants with episodic Cluster Headache (eCH)
What is the current status of trial NCT04688775?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 231 participants. The study started on 2020-12-23. Estimated completion is 2023-10-05.
What interventions are being tested in trial NCT04688775?
The interventions under investigation include: Placebo (DRUG), Eptinezumab (DRUG).
Who is sponsoring clinical trial NCT04688775?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.